Series B

With a fresh $55M led by Khosla Ventures, Bunkerhill Health is deploying agentic AI to bridge healthcare's operational gaps and save lives. Here's why.

With a fresh $150M, Mighty Therapeutics is set to expand its groundbreaking mitochondrial drugs from rare diseases to major conditions like Parkinson's.

A new partnership between AI platform Agentio and Meta promises to automate creator advertising, swapping manual deals for data-driven performance.

MindRank's AI platform propelled a GLP-1 drug to Phase III in record time. Its new $52M funding aims to prove this isn't a one-off, but a revolution.

With a multi-million-dollar Series B, Kuehnle AgroSystems is commercializing a novel tech that promises to upend the $2B natural astaxanthin market.

As AI moves from training to production, a new infrastructure battle begins. DeepInfra's Canadian expansion reveals the race for low-latency, global inference.

Pediatrica Health's $28M Series B aims to fix a broken system. With investors betting on 'equitable access,' is this the future of child healthcare?

HMNC Brain Health's new oral ketamine shows promise by minimizing side effects, but an unmet endpoint raises questions. Is this the key to at-home TRD care?

A Vancouver firm's tech promises to turn low-grade ore into pure copper and green hydrogen, testing a new model for mining that values execution over extraction.

A new custom rug showroom in Fairfax is more than just a store; it’s a look into the future of retail, where personalization, speed, and experience collide.

Oblenio Bio's oversubscribed Series B will advance a novel tri-specific T-cell engager, aiming to reset the immune system without harsh side effects.

Ollin Biosciences secured $330M to challenge giants like Roche and Regeneron. Their next-gen antibody shows early promise in treating vision loss.

With a fresh $81M in funding and a $1.25B valuation, Redo is moving beyond returns, betting on AI and a key acquisition to build the future of commerce.

With a fresh $190M, Osanni Bio is pioneering a radical new model for drug discovery—building an ecosystem of specialized spinoffs to accelerate cures.

With a fresh $50M from a top tech investor, Partly is bringing its purpose-built AI to the US, aiming to overhaul the analog chaos of auto parts.

A new breed of AI is moving beyond recording sales calls to actively running the workflow. We dissect Attention's $30M Series B and the rise of agentic AI.

With a $43M funding boost, Irish innovator CroíValve is expanding trials for its unique 'Adaptive Coaptation' device, aiming to transform treatment for millions.

With $75M from Index Ventures, fomo aims to abstract crypto's complexity, blending social features with a user-friendly interface for the next wave of traders.

A Chinese city is investing billions to become a global satellite hub, unveiling ambitious plans for carbon monitoring and international partnerships. Is this a tech boom or a new front in space geopolitics?

A startup's $1B valuation for building AI-powered offensive cyber tools signals a defense tech gold rush. But who is accountable when private code goes to war?